|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Assessment of drug-induced hepatotoxicity in clinical practice: A challenge for gastroenterologists显示文摘Currently, pharmaceutical preparations are serious contributors to liver disease; hepatotoxicity ranking as the most frequent cause for acute liver failure and post-commercialization regulatory decisions. The diagnosis of hepatotoxicity remains a difficult task because of the lack of reliable markers for use in general clinical practice. To incriminate any given drug in an episode of liver dysfunction is a step-by-step process that requires a high degree of suspicion, compatible chronology, awareness of the drug’s hepatotoxic potential, the exclusion of alternative causes of liver damage and the ability to detect the presence of subtle data that favors a toxic etiology. This process is time-consuming and the final result is frequently inaccurate. Diagnostic algorithms may add consistency to the diagnostic process by translating the suspicion into a quantitative score. Such scales are useful since they provide a framework that emphasizes the features that merit attention in cases of suspected hepatic adverse reaction as well. Current efforts in collecting bona fide cases of drug-induced hepatotoxicity will make refinements of existing scales feasible. It is now relatively easy to accommodate relevant data within the scoring system and to delete low-impact items. Efforts should also be directed toward the development of an abridged instrument for use in evaluating suspected drug-induced hepatotoxicity at the very beginning of the diagnosis and treatment process when clinical decisions need to be made. The instrument chosen would enable a confident diagnosis to be made on admission of the patient and treatment to be fine-tuned as further information is collected. | Raúl J Andrade Mercedes Robles Alejandra Fernández-Castaer Susana López-Ortega M Carmen López-Vega M Isabel Lucena | 2007 | World Journal of Gastroenterology2007，13，3： | 18 |
| 2 | drug-induced autoimmune liver disease:a diagnostic dilemma of an increasingly reported disease显示文摘The aetiology of autoimmune hepatitis(AIH) is uncer-tain but the disease can be triggered in susceptible patients by external factors such as viruses or drugs.AIH usually develops in individuals with a genetic back-ground mainly consisting of some risk alleles of the major histocompatibility complex(HLA).Many drugs have been linked to AIH phenotypes,which sometimes persist after drug discontinuation,suggesting that they awaken latent autoimmunity.At least three clini-cal scenarios have been proposed that refers to drug- induced autoimmune liver disease(DIAILD):AIH with drug-induced liver injury(DILI); drug induced-AIH(DI-AIH); and immune mediated DILI(IM-DILI).In addi-tion,there are instances showing mixed features of DI-AIH and IM-DILI,as well as DILI cases with positive autoantibodies.Histologically distinguishing DILI from AIH remains a challenge.Even more challenging is the differentiation of AIH from DI-AIH mainly relying in histological features; however,a detailed standard-ised histologic evaluation of large cohorts of AIH and DI-AIH patients would probably render more subtle features that could be of help in the differential diag-nosis between both entities.Growing information on the relationship of drugs and AIH is being available,being drugs like statins and biologic agents more fre-quently involved in cases of DIAILD.In addition,there is some evidence on the fact that patients diagnosed with DIAILD may have had a previous episode of hepa-totoxicity.Further collaborative studies in DIAILD will strengthen the knowledge and understanding of this intriguing and complex disorder which might represent different phenotypes across the spectrum of | Agustin Castiella Eva Zapata M Isabel Lucena Raúl J Andrade | 2014 | World Journal of Hepatology2014，6，4： | 13 |
| 3 | Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in VigiBase(TM)显示文摘 | Suzuki Ayako Andrade Raul J Bjornsson Einar Lucena M Isabel Lee William M Yuen Nancy A Hunt Christine M Freston James W | 2010 | Drug Safety2010，，6： | 2 |
| 4 | How to manage inflammatory bowel disease during the COVID-19 pandemic:A guide for the practicing clinician显示文摘Managing inflammatory bowel disease(IBD)during the coronavirus disease 2019(COVID-19)pandemic has been a challenge faced by clinicians and their patients,especially concerning whether to proceed with biologics and immunosuppressive agents in the background of a global outbreak of a highly contagious new coronavirus(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2).The knowledge about the impact of this virus on patients with IBD,although it is still scarce,is rapidly evolving.In particular,concerns surrounding medications’impact for IBD on the risk of acquiring SARS-CoV-2 infection or developing COVID-19,and potentially exacerbate viral replication and the COVID-19 course,are a current thinking of both practicing clinicians and providers caring for patients with IBD.Managing patients with IBD infected with SARS-CoV-2 depends on both the clinical activity of the IBD and the occasional development and severity of COVID-19.In this review,we summarize the current data regarding gastrointestinal involvement by SARS-CoV-2 and pharmacologic and surgical management for IBD concerning this infection,and the COVID-19 impact on both the patient's psychological functioning and endoscopy services,and we concisely summarize the telemedicine roles during the COVID-19 pandemic. | Júlio Maria Fonseca Chebli Natália Sousa Freitas Queiroz Adérson Omar Mourão Cintra Damião Liliana Andrade Chebli Márcia Henriques de Magalhães Costa Rogério Serafim Parra | 2021 | World Journal of Gastroenterology2021，27，11： | 2 |
| 5 | Personalized medicine in gastric cancer:Where are we andwhere are we going?显示文摘Despite improvements in adjuvant therapies for gastric cancer in recent years, the disease is characterized by high recurrence rates and a dismal prognosis. The major improvement in the treatment of recurrent or metastatic gastric cancer in recent years has been the incorporation of trastuzumab, a monoclonal antibody that inhibits human epidermal growth factor receptor 2(HER2) heterodimerization, after the demonstrated predictive value of the overexpression and/or amplification of this receptor. Beyond HER2, other genetic abnormalities have been identified, and these mutations may be targetable by tyrosine kinase inhibitors or monoclonal antibodies. The demonstration of four distinct molecular subtypes of gastric cancer by the Cancer Genome Atlas study highlight the enormous heterogeneity of the disease and its complex interplay between genetic and epigenetic alterations and provide a roadmap to implement genome-guided personalized therapy in gastric cancer. In the present review, we aim to discuss, from a clinical point of view, the genomic landscape of gastric cancer described in recent studies, the therapeutic insights derived from these findings, and the clinical trials that have been conducted and those in progress that take into account tailored therapies for gastric cancer. | Alexandre A Jácome Anelisa K Coutinho Enaldo M Lima Aline C Andrade JoséSebastião dos Santos | 2016 | World Journal of Gastroenterology2016，22，3： | 2 |
| 6 | Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: Is there still a role for these drugs?显示文摘四乙秋兰姆化二硫和钙 carbimide 是二白酒威慑然而,广泛地在那里在酒精中毒治疗使用的狂言存在对他们的安全的大担心。hepatotoxicity 上的报告主要与四乙秋兰姆化二硫治疗有关,被出版了。钙 carbimide 的肝毒素的潜力是很好描绘的更少。这里,我们描述与被提交到 hepatotoxicity 的一张注册表并且当规定这些混合物时,指出我们面对的限制的这个治疗学的组有关的肝损坏的四个案例。对在白酒依赖的管理的这些混合物的角色的重估清楚地被需要。 | Carmen Verge M Isabel Lucena Enrique López-Torres M José Puche-García Enrique Fraga Manuel Romero-Gomez Raúl J Andrade | 2006 | World Journal of Gastroenterology2006，12，31： | 2 |
| 7 | Evolution of pore solution chemistry, electro-osmosis and rehar corrosion rate induced by realkalisation显示文摘 | ANDRADE C CASTELLOTE M SARRIA J | 1999 | Materials and Structures1999，32，220： | 1 |
| 8 | The influence of thermal cycling on the transition temperatures of a Fe-Mn-Si shape memory alloy显示文摘 | Andrade M S Osthues R M Arruda G J | 1999 | Materials Science and Engineering A1999，，： | 1 |
| 9 | 显示文摘 | Lima M D de Andrade M J Bergmann C P | 2008 | J Mater Chem2008，18，： | 1 |
| 10 | Chemical composition of lipophilic extractives from jute (Corchorus capsularis)fibers used for manufacturing of high-quality paper pulps 显示文摘 | Rio Andrade J C Marques G Rodriguez Garcia M I | 2009 | Industrial Crops and Products2009，30，： | 1 |
| 11 | A dose response study following in utero and lactational exposure to di-(2-ethylhexyl)phthalate(DEHP):Reproductive effects on adult male offspring rats显示文摘 | Andrade A J M Grande S W Talsness C E | | 0，，01： | 1 |
| 12 | Thermo-rheological behavior of model protein-polysaccharide mixtures 显示文摘 | Andrade R J Azevedo A G Musampa R M | 2010 | Rheologica Acta2010，49，4： | 1 |
| 13 | The comparison of two heavy fuel oils in composition and weathering pat- tern, based on IR, GC-FID and GC-MS analyses: Application to the Prestige wreackage显示文摘 | Ferndndez-Varela R Andrade J M Muniategui S | 2009 | Water research2009，43，4： | 1 |
| 14 | Successful preservation of fertility subsequent to a complete pathologic response of a squamous cell carcinama of the uterine cervix treated with primary systemic chemotherapy显示文摘 | Andrade J M Marana H R Mangieri L F | 2000 | Gynecol Oncol2000，77，1： | 1 |
| 15 | Efficiency of different clay minerals modified with a eationic surfactant in the adsorption of pesticides: influence of clay type and pesticide hydrophobie 显示文摘 | SANCHEZ M M J RODRIGUEZ C M S ANDRADES M S | 2006 | Applied Clay Science2006，31，34： | 1 |
| 16 | Production of 1,3-propanediol by Clostridium butyrieum VPI 3266 using a synthetic medium and raw glycerol 显示文摘 | Gonza'lez Pajuelo M Andrade J C Vaseoncelos I | 2004 | J Ind Microbial Biotechnol2004，31，9： | 1 |
| 17 | The real-timepolymerase chain reaction显示文摘 | Kubista M Andrade J M Bengtsson M | 2006 | Mol Aspects Med2006，27，23： | 1 |
| 18 | Phytoestrogens and breast cancer: a complex story 显示文摘 | Helfefich W G Andrade J E Hoagland M S | 2008 | Inflammopharmacology2008，16，5： | 1 |
| 19 | Strain specificity of yeasts isolated from different locations of women suffering from vaginal candidosis,and their partners显示文摘 | Mendling W Pinto De Andrade M Gutschmidt J | 2000 | Mycoses2000，43，： | 1 |
| 20 | 显示文摘 | Santos RA Campagnole-Santos M J Andrade SP | 2000 | Regul Peptide2000，91，13： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员